CEO
AP
Ablaze Pharmaceuticals
The startup develops targeted radiotherapy (TRT) treatments tailored to the clinical stage of cancer, utilizing precise delivery methods to enhance treatment efficacy. By introducing these TRT products to the Chinese market, the company aims to improve patient outcomes and access to effective cancer therapies.
- Biotechnology
- Healthcare Technology
Updated 23 months ago
Funding
Raised to date
$75MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops targeted radiotherapy (TRT) treatments tailored to the clinical stage of cancer, utilizing precise delivery methods to enhance treatment efficacy. By introducing these TRT products to the Chinese market, the company aims to improve patient outcomes and access to effective cancer therapies.